Latin American countries to set up central medicines regulator
This article was originally published in Scrip
Medicines produced in Latin America's left-wing ALBA group member countries could soon be approved and registered by a central regulator.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.